Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi SA (NASDAQ:SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

Sales increased 6% year over year, up 10.1% in constant currency, driven by growth in Immunology, pharmaceutical launches and Beyfortus.

The French drug maker reported that in the second quarter of 2025, business operating income reached € 2.46 billion, down 2.4% year over year, and up 3% in constant currency.

First-half operating income jumped to €5.36 billion, up 8.6% (+10.8%).

The reported adjusted EPS of 1.59 euros or 90 cents per ADS, missing the consensus of 96 cents, up 1.9% (+8.3% on constant currency).

Pharma launches increased sales by 39.8%, reaching € 897 million, driven by ALTUVIIIO sales of €291 million, up 91.8% at constant currency.

Dupixent sales increased by 21.1% to 3.83 billion Euros, supported by the launch of COPD.

Also ...